General form of registration statement for all companies including face-amount certificate companies

Segment Reporting (Details)

v3.7.0.1
Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]            
Revenues - external customers $ 37 $ 379 $ 247 $ 673 $ 948 $ 1,851
Revenue From Intersegment 0 0 0 0    
Research and development 1,136 1,048 3,005 2,303 3,156 3,495
General and administrative 2,837 2,403 7,657 5,509 7,685 5,022
Operating loss (3,936) (3,072) (10,415) (7,139) (9,893) (6,666)
Interest expense (481) (323) (1,447) (323) (807) 0
Interest and other income 12 10 53 26 43 41
Consolidated net loss (4,405) (3,385) (11,809) (7,436) (10,657) (6,625)
Total assets 40,698 50,665 40,698 50,665 51,600 12,494
Fixed assets, net 25,794 25,775 25,794 25,775 25,574 13
Intangible assets, net 1,895 2,139 1,895 2,139 2,092 2,360
Depreciation expense 337 261 987 263 577 5
Amortization of intangible assets 88 92 264 274 363 358
Intersegment Eliminations [Member]            
Segment Reporting Information [Line Items]            
Revenues - external customers 0 0 0 0    
Revenue From Intersegment (644) (129) (1,645) (129)    
Research and development (369) (129) (968) (129)    
General and administrative (275) 0 (677) 0    
Operating loss 0 0 0 0    
Interest expense 0 0 0 0    
Interest and other income 0 0 0 0    
Consolidated net loss 0 0 0 0    
Total assets (12,555) (40) (12,555) (40)    
Fixed assets, net 0 0 0 0    
Intangible assets, net 0 0 0 0    
Depreciation expense 0 0 0 0    
Amortization of intangible assets 0 0 0 0    
iBio Brazil [Member]            
Segment Reporting Information [Line Items]            
Revenues - external customers         0 0
Research and development         0 0
General and administrative         22 93
Operating loss         (22) (93)
Interest expense         0 0
Interest and other income         0 0
Consolidated net loss         (22) (93)
Total assets         20 46
Fixed assets, net         0 10
Intangible assets, net         0 0
Depreciation expense         2 2
Amortization of intangible assets         0 0
iBio United States [Member]            
Segment Reporting Information [Line Items]            
Revenues - external customers         948 1,851
Research and development         3,156 3,495
General and administrative         7,663 4,929
Operating loss         (9,871) (6,573)
Interest expense         (807) 0
Interest and other income         43 41
Consolidated net loss         (10,635) (6,532)
Total assets         51,580 12,448
Fixed assets, net         25,574 3
Intangible assets, net         2,092 2,360
Depreciation expense         575 3
Amortization of intangible assets         $ 363 $ 358
Ibio Inc [Member] | Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Revenues - external customers 0 371 161 665    
Revenue From Intersegment 283 0 695 0    
Research and development 1,033 951 2,733 2,192    
General and administrative 1,276 1,532 3,864 4,550    
Operating loss (2,026) (2,112) (5,741) (6,077)    
Interest expense 0 0 0 0    
Interest and other income 8 8 35 24    
Consolidated net loss (2,018) (2,104) (5,706) (6,053)    
Total assets 20,573 11,015 20,573 11,015    
Fixed assets, net 8 13 8 13    
Intangible assets, net 1,895 2,139 1,895 2,139    
Depreciation expense 1 2 3 4    
Amortization of intangible assets 88 92 264 274    
iBio CMO [Member] | Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Revenues - external customers 37 8 [1] 86 8 [1]    
Revenue From Intersegment 361 129 [1] 950 129 [1]    
Research and development 472 226 [1] 1,240 240 [1]    
General and administrative 1,836 871 [1] 4,470 959 [1]    
Operating loss (1,910) (960) [1] (4,674) (1,062) [1]    
Interest expense (481) (323) [1] (1,447) (323) [1]    
Interest and other income 4 2 [1] 18 2 [1]    
Consolidated net loss (2,387) (1,281) [1] (6,103) (1,383) [1]    
Total assets 32,680 39,690 [1] 32,680 39,690 [1]    
Fixed assets, net 25,786 25,762 [1] 25,786 25,762 [1]    
Intangible assets, net 0 0 [1] 0 0 [1]    
Depreciation expense 336 259 [1] 984 259 [1]    
Amortization of intangible assets $ 0 $ 0 [1] $ 0 $ 0 [1]    
[1] iBio CMO commenced operations in December 2015